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AbstrACt
Introduction Major depressive disorders (MDD), diabetes 
mellitus type 2 (DM2) and coronary heart disease (CHD) 
are leading contributors to the global burden of disease 
and often co-occur.
Objectives To evaluate the 2-year effectiveness of a 
stepped-care intervention to prevent MDD compared 
with usual care and to develop a prediction model for 
incident depression in patients with DM2 and/or CHD with 
subthreshold depression.
Methods Data of 236 Dutch primary care patients with 
DM2/CHD with subthreshold depression (Patient Health 
Questionnaire 9 (PHQ-9) score ≥6, no current MDD 
according to the Mini International Neuropsychiatric 
Interview (Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition criteria)) who participated in 
the Step-Dep trial were used. A PHQ-9 score of ≥10 
at minimally one measurement during follow-up (at 
3, 6, 9, 12 and 24 months) was used to determine the 
cumulative incidence of MDD. Potential demographic and 
psychological predictors were measured at baseline via 
web-based self-reported questionnaires and evaluated 
using a multivariable logistic regression model. Model 
performance was assessed with the Hosmer-Lemeshow 
test, Nagelkerke’s R2 explained variance and area 
under the receiver operating characteristic curve (AUC). 
Bootstrapping techniques were used to internally validate 
our model.
results 192 patients (81%) were available at 2-year 
follow-up. The cumulative incidence of MDD was 97/192 
(51%). There was no statistically significant overall 
treatment effect over 24 months of the intervention (OR 
1.37; 95% CI 0.52 to 3.55). Baseline levels of anxiety, 
depression, the presence of >3 chronic diseases and 
stressful life events predicted the incidence of MDD 
(AUC 0.80, IQR 0.79–0.80; Nagelkerke’s R2 0.34, IQR 
0.33–0.36).
Conclusion A model with 4 factors predicted depression 
incidence during 2-year follow-up in patients with 
DM2/CHD accurately, based on the AUC. The Step-Dep 
intervention did not influence the incidence of MDD. Future 
depression prevention programmes should target patients 
strengths and limitations of this study
 ► This study provides a prediction model of incident 
major depressive disorder (MDD) in patients  with 
diabetes mellitus type 2 and/or coronary heart dis-
ease with subthreshold depression, which could 
assist healthcare providers in its detection and fa-
cilitate targeting indicated prevention to highest-risk 
patients.
 ► Only predictors that are readily available or easily 
obtained in practice were used in the multivariable 
model, which enhances the practical use of the 
model.
 ► This study had a relatively long follow-up and out-
comes were frequently measured, whereas drop-
out rates were relatively low and missing values 
imputed.
 ► The relatively small study population might have 
caused overoptimism of the prediction model, but 
an internal validation procedure with bootstrapping 
techniques showed that this risk was minor.
 ► Data were derived from a randomised controlled 
trial, but statistically non-significant intervention 
effects for incident MDD at both 12 and 24 months 
follow-up justify using the Step-Dep population as 
a cohort.
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with these 4 predictors present, and aim to reduce both anxiety and 
depressive symptoms.
trial registration number NTR3715.
IntrOduCtIOn  
Depression is a major and increasing contributor to the 
global burden of disease,1 whereas coronary heart disease 
(CHD) and diabetes mellitus type 2 (DM2) rank among 
the leading causes of morbidity and mortality worldwide.2 
Comorbid depression in patients with DM2 and/or CHD 
is common3 4 and has detrimental effects on self-care 
and medication adherence,5 6 quality of life7 and health 
status and increases healthcare costs8 9 and mortality.10 11 
Despite its negative impact, many cases of depression go 
unrecognised in primary care,12 especially in patients 
with chronic diseases like DM2 and/or CHD.13 Addition-
ally, about one-third of those recognised and treated does 
not respond to current approaches, and over half of those 
who experience a first onset of a major depressive episode 
will experience one or more recurrences.14 
Given the significant burden of disease of depression, 
its poor recognition and the limited effect of current 
treatment options for it, it would be of great value if 
incident cases could be averted by early detection and 
preventive treatment of patients at risk (‘indicated 
prevention’). Meta-analyses have shown that preven-
tive psychological interventions can overall reduce 
the incidence of major depressive disorder (MDD) in 
comparison to control groups.15 16 Offering preventive 
psychological interventions in a stepped-care format 
could be an efficient approach, as patients start with mini-
mally intensive evidence-based treatments and only those 
who do not improve adequately step up to a treatment of 
higher intensity.17 Recently, we conducted a randomised 
controlled trial (RCT) in which we evaluated whether a 
pragmatic nurse-led stepped-care programme was effec-
tive in reducing the incidence of MDD at 12 months of 
follow-up in comparison with usual care among patients 
with DM2 and/or CHD and subthreshold depression 
(Step-Dep).18 Subthreshold depression entails clinically 
relevant depressive symptoms without fulfilling the criteria 
for MDD and is a known important risk factor for depres-
sion.15 19 We demonstrated that the Step-Dep intervention 
was not superior to usual care and the overall cumulative 
incidence of MDD was lower than expected after 1 year.20 
However, it may be possible that the follow-up period was 
too restricted to demonstrate the potential health bene-
fits of the stepped-care programme over usual care, or 
the presence of subthreshold depression alone posed a 
lower than expected prior risk of MDD in our DM2 and/
or CHD population.
Identifying additional major risk factors of incident 
depression in patients with DM2 and/or CHD might 
facilitate targeting indicated prevention to patients with 
highest risk, but also potentially aid in its detection. In 
patients with DM2, several longitudinal studies have been 
conducted to determine risk factors for comorbid incident 
depression. However, these studies have rendered hetero-
geneous results, due to small patient samples (<80 at 
follow-up),21 22 analyses of single factors only,23 24 the use 
of mixed samples of type 1 diabetes and DM2,25 patients 
with either no MDD at baseline21 23 or both with and 
without depression at baseline22 24–26 and differences 
across community,23 24 primary care25 26 and secondary 
care settings.21 22 In patients with CHD, the only available 
longitudinal data are derived from studies in patients 
with acute coronary syndrome followed-up after hospital 
discharge.27–31 Predictors that were repeatedly identi-
fied in DM2 or CHD studies were: depression severity at 
baseline,21 22 25 27 30 31 history of depression,25 26 28 female 
sex24 26 28 30 and baseline anxiety levels.21 29 30 However, 
data of patients with both DM2 and CHD, non-acute 
CHD or within primary care settings are scarce. The goal 
of the present study was twofold: (1) to evaluate the 2-year 
effectiveness of a nurse-led stepped-care intervention to 
prevent MDD as compared with usual care (Step-Dep); 
and to (2) develop a prediction model for incident depres-
sion during 2-year follow-up in primary care patients with 
DM2 and/or CHD and subthreshold depression.
MethOds
design
Data of the Step-Dep cluster RCT were used. Step-Dep 
was conducted in 27 general practitioner (GP) practices 
in 3 regions in the Netherlands (Amsterdam, Leiden and 
Twente), between January 2013 and November 2016, 
including recruitment and 2 years of follow-up. A statis-
tician blinded to the characteristics of the GP practices 
performed the randomisation of GP practices using a 
computer-generated list of random numbers. Randomi-
sation was done at the level of the GP practice, which 
corresponds to the participating practice nurse, to avoid 
contamination between the treatment groups, and was 
stratified for size (less or more than 5000 patients). The 
study was performed in accordance with the declara-
tion of Helsinki (2008) and the Dutch Medical Research 
involving Human Subjects Act (WMO). The protocol 
was approved (NL39261.029.12, registration number 
2012/223), and registered in the Dutch Trial Register 
(NTR3715 http://www. trialregister. nl/ trialreg/ admin/ 
rctview. asp? TC= 3715). The evaluation of predictors of 
incident depression were not prespecified in designing 
the study. Further details on the methods and design of 
the Step-Dep study have been published elsewhere.18
Patient and public involvement
Patients were not involved in determining the design, the 
recruitment to or conduct of the study. The medical ethics 
committee of the VU University Medical Centre assessed 
the burden of the intervention and participation in the 
study in general as acceptable for patients. The burden 
of and satisfaction with the intervention were assessed 
in a process evaluation with 15 patients. All patients are 
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thanked in the acknowledgements section. Results of the 
study will be disseminated by letter to all participants.
Patients
Included patients were aged 18 years or more who had an 
International Classification of Primary Care (ICPC) diag-
nosis of DM2 and/or CHD and had subthreshold depres-
sion identified by screening. Patients with a Patient Health 
Questionnaire 9 (PHQ-9; range 0–27 with higher scores 
indicating more severe depressive symptoms) score of 6 
or higher,32 33 and no MDD according to the Mini Inter-
national Neuropsychiatric Interview (MINI),34 35 were 
considered to have subthreshold depression. Exclusion 
criteria were cognitive impairment, psychotic illnesses, a 
terminal illness, the use of antidepressant medication, a 
history of suicide attempt(s), loss of significant other in 
the past 6 months, visual impairment, current pregnancy, 
bipolar disorder, borderline personality disorder or any 
difficulties completing written questionnaires or visiting 
the primary care centre. A total of 236 patients gave 
informed consent to participate.
Outcome measure
The outcome measure used was an incident depression 
(yes/no) defined as a PHQ-9 score of ≥10 at minimally 
one moment during follow-up (measured at 3, 6, 9, 12 
and 24 months after baseline). The PHQ-9 is a widely used 
and validated instrument that performs well in patients 
with chronic medical illnesses both as dichotomous diag-
nosis of major and minor depression and a continuous 
severity score.33 36 A cut-off of ≥10 has been shown to be 
the optimum cut-off for major depression,37 also in this 
patient group.38 PHQ-9 was self-reported with web-based 
or written questionnaires. When these web-based or 
written questionnaires were not completed, the PHQ-9 
was administered by telephone by trained research assis-
tants, blinded to randomisation status.
Potential predictors
The selection of the potential predictors was based on a 
thorough literature search. Predictors of incident depres-
sion that were identified in multiple studies in patients 
with DM2 or CHD and are routinely available or easily 
obtained in daily GP practice were used. Additionally, we 
chose the presence of multiple chronic diseases24 and 
stressful life events27 although they were identified in 
single studies only, as these were also indicated as causes 
of depression by patients and practice nurses in semi-
structured interviews as part of the process evaluation of 
Step-Dep (Pols, submitted) and age.23
Apart from GP information system-derived data on sex, 
age and ICPC diagnosis of DM2 and/or CHD, demo-
graphics and psychological factors were measured at base-
line via web-based (or written if preferred) self-reported 
questionnaires. To take possible effects of the interven-
tion into account, we included randomisation status in 
the selection models as well. Patients in the intervention 
arm were offered a stepped-care prevention programme, 
and patients in the control arm received care as usual 
during 1 year. The stepped-care intervention consisted 
of 4 sequential but flexible treatment steps, each lasting 
3 months: (1) watchful waiting, (2) guided self-help, (3) 
problem solving treatment and (4) referral to a GP. After 
each step, patients with a persisting PHQ-9 score of 6 or 
more were offered the next treatment step of the inter-
vention. Baseline depression levels were measured with 
the PHQ-9.32 33 Baseline anxiety levels were measured 
with the Hospital Anxiety and Depression Scale Anxiety 
(HADS-A; range 0–21 with higher scores indicating more 
severe anxiety).39 History of depression and stressful 
life events were self-reported using a subset of the Diag-
nostic Interview Schedule.40 Number of comorbid 
chronic illnesses was measured using the self-reported 
Dutch Questionnaire Chronic Illnesses.41 This was dichot-
omised using the median in our sample: 3 or less versus 
more than 3 chronic diseases.
statistical analyses
The 2-year effectiveness of the intervention on the 
primary and secondary outcomes was analysed according 
to the intention to treat principle. Generalised estimating 
equations were used for binary outcome variables, and 
linear mixed models for longitudinal data were used for 
continuous outcome variables.42 For each outcome, an 
overall effect over time and separate effects at different 
time points were estimated by taking time into account 
as a categorical variable (with 5 categories: 0–3 months, 
3–6 months, 6–9 months, 9–12 months and 12–24 months 
of follow-up).43 44 The main analyses consisted of fully 
corrected models that were corrected for baseline values 
of the respective outcome and additionally included 
the covariates gender,45 age46 and any other possible 
confounding variable on which the treatment groups 
differed at baseline (marital status, employment status, 
level of education, coexistence of DM2 and CHD, alcohol 
use, number of depressive episodes in history and age of 
onset of depression), based on absolute baseline differ-
ences judged by the researchers rather than statistical 
testing.47 For these analyses, STATA V.14 was used.
Missing data were imputed using multiple imputation 
according to the multivariate imputation by chained 
equations algorithm48 in SPSS V.23. For the imputations, 
missing at random was assumed. Variables that were asso-
ciated with missing data and variables that were associ-
ated with the outcome were identified and included in 
the imputation model. Also, all variables in the analysis 
model (potential predictors and outcome) were included. 
The number of imputed datasets was 25 based on the 
proportion of cases with incomplete measurements, 24%. 
The subsequent analyses were performed on pooled data 
according to Rubin’s rules.49
Prediction model
We created a multivariable logistic regression model in 
SPSS V.23 from the baseline variables estimating the prob-
ability of having at least one major depression (PHQ ≥10) 
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during the 2-year assessment. To calculate the number 
of potential predictors for developing the prediction 
model, we used the criterion of 10 events per variable. 
Continuous variables were checked for linearity with the 
outcome using spline regression curves and linearity was 
confirmed. All variables were entered into the logistic 
model and tested for statistical significance in the pres-
ence of the total set of predictors. Subsequently, the least 
significant predictor (p value >0.157, as recommended in 
the Transparent Reporting of a multivariable prediction 
model for Individual Prognosis or Diagnosis statement,50 
Wald statistic) was removed, and the model was refit 
(backward selection). Randomisation status was main-
tained in the model. This was repeated until we reached 
a statistical model that only included statistically signifi-
cant predictors. This process was repeated with p values 
of 0.05. We also compared the results with complete case 
analysis (CCA), that is, all patients with missing data were 
excluded from the analyses.
We checked the performance of the model with regard 
to the goodness of fit (Hosmer-Lemeshow test), the 
explained variation and the discriminative ability of the 
model. The Nagelkerke’s R2 explained variation is the 
extent to which the outcome can be predicted by the 
predictors in the model in current data sets. The discrim-
inative ability is reflected by the area under the receiver 
operating characteristics curve (AUC). Bootstrapping 
techniques were used to internally validate our model, 
that is, to simulate the performance with respect to the 
explained variance and the AUC in comparable patient 
data sets.51 After that, we calculated the linear predictor 
of the bootstrapped model with an adjusted intercept and 
regression coefficients corrected for the shrinkage factor. 
Performance measures were assessed in each imputed 
data set and results were summarised using median 
values.52 All analyses were done with SPSS V.23.0 and R 
software.
results
Participants
The baseline characteristics of the study population 
are presented in table 1. Of the 236 patients included 
in Step-Dep, 192 patients (81%) completed 2 years of 
follow-up. A flowchart of participants through the first 12 
months of the Step-Dep study has been published else-
where.20 At 24 months of follow-up, 18 additional patients 
dropped out (2 for unknown motives, 7 due to time 
considerations, 4 were deceased, 3 too frail and 2 unable 
to contact). We compared the baseline characteristics of 
patients with missing data to those without. Patients with 
missing data were more often living alone (61% vs 41%), 
but no other differences between these groups were 
found.
There was no statistically significant overall treatment 
effect over 24 months of the intervention (OR 1.37; 95% CI 
0.52 to 3.55), nor at any of the time points. There were 
no significant differences in PHQ-9 scores between the 
study groups at any time point and the course of PHQ-9 
scores over time did not differ significantly between the 
groups. Results are shown in table 2. The statistically 
non-significant intervention effects for incident MDD at 
both 12 months20 and 24 months of follow-up justify using 
the Step-Dep population as a cohort.
Prediction model
The cumulative incidence during 2-year follow-up was 
97/192 (51%). The multivariable models using p=0.05 and 
p=0.15750 were identical. The final model consisted of 4 
predictors: level of anxiety, level of depression, presence 
of more than 3 chronic diseases and having suffered a 
stressful life event in the past year. This model performed 
well (Hosmer-Lemeshow test p=0.12 and median of 
pooled Nagelkerke’s R2 explained variance 0.34 IQR 
0.33–0.36) with good discriminative properties (median 
of the pooled AUC 0.80, IQR 0.79–0.80). In a CCA with 
p=0.05, the same predictors remained. In a CCA using 
p=0.157,50 the categorical variable DM2/CHD/both also 
remained.
The risk of an incident MDD during 2 years of follow-up 
more than doubled when either more than 3 chronic 
diseases were present or a patient had suffered a stressful 
life event in the past year. Both higher depression and 
anxiety levels at baseline increased the risk of MDD with 
each incremental point on the PHQ-9 of the HADS 
scales, respectively. One point higher on the PHQ-9 
at baseline resulted in a 1.37 higher risk of developing 
MDD during 2 years, compared with 1.13 for increasing 
anxiety levels. With regard to the internal validation of 
the model, the calibration slope (or shrinkage factor to 
correct regression coefficients of the original model) was 
0.92 IQR 0.91–0.92, the median explained variance was 
31% IQR 0.29–0.32 and the AUC 0.78 IQR 0.77–0.78. 
This means that after corrections for overoptimism, both 
the performance and discriminative properties of the 
model remained good. Results are shown in table 3.
dIsCussIOn
This study showed that the Step-Dep intervention was 
not more effective than usual care in the prevention of 
MDD at 2 years of follow-up. The risk of incident MDD 
during 2 years of follow-up among patients with DM2 
and/or CHD and subthreshold depression was increased 
by higher baseline levels of anxiety and depression, the 
presence of more than 3 chronic diseases and having 
suffered a stressful life event in the past year. This risk was 
not influenced by a stepped-care intervention aimed at 
preventing MDD.
Our findings have to be viewed in the context of 
strengths and limitations of this study. Strengths are its 
relatively long follow-up with frequent outcome measure-
ments and low dropout rates. In addition, missing values 
were imputed using multiple imputation techniques. We 
only used predictors that are readily available or easily 
obtained in practice, which enhances the practical use 
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of the model in primary care consultations. Further-
more, testing a multivariable model instead of single 
factors appointed only the most relevant predictors, 
which rendered a simple model that is manageable in its 
use. There were limitations to this study. First, the study 
population was relatively small, which might have caused 
overoptimism of the prediction model. This means that it 
predicts the outcome better in the sample used to develop 
the model than in new samples, potentially restricting its 
external validity. However, an internal validation proce-
dure with bootstrapping techniques showed that this risk 
was minor. Second, we used data derived from a RCT 
instead of a cohort, which potentially limits the gener-
alisability of our results. Third, we evaluated a limited 
number of predictors in this study and genetic and other 
biological risk indicators, for example, were not included. 
This was due to the relatively small population size and 
our preselection criteria for potential predictors: predic-
tors had to be both identified before in multiple studies 
and easily obtainable in GP practice. Finally, in this study, 
the use of the PHQ-9 with a cut-off score of 10 or more 
rendered a higher cumulative incidence of depression 
than the MINI. This could be explained by the fact that 
the PHQ-9 was measured more frequently than the MINI. 
Also, the PHQ-9 was self-reported instead of administered 
with a diagnostic interview by a trained research assistant. 
However, it is possible that depression was sometimes 
overdiagnosed with the PHQ-9 due to potential overlap 
Table 1 Patients’ baseline characteristics at baseline in intervention group, care as usual group and total sample
Characteristics Total sample (n=236) Intervention (n=96) Care as usual (n=140)
Female 107/236 (45.3) 42/96 (43.8) 65/140 (46.4)
Age, mean (SD) 67.5 (10.0) 67.8 (9.2) 67.3 (10.5)
Stressful life event 112/210 (53.3) 48/89 (53.9) 64/121 (52.9)
Positive history of depression 113/210 (53.8) 54/89 (60.7) 59/121 (48.8)
ICPC diagnosis (diabetes mellitus type 2 (DM2) 
and/or coronary heart disease (CHD)
  DM2 88/236 (37.3) 38/96 (39.6) 50/140 (35.7)
  CHD 86/236 (36.4) 36/96 (37.5) 50/140 (35.7)
  DM2 and CHD 62/236 (26.3) 22/96 (22.9) 40/140 (28.6)
More than 3 chronic diseases 98/210 (46.7) 38/89 (42.7) 60/121 (49.6)
PHQ-9 at baseline, mean (SD) 9.4 (3.2) 9.5 (3.1) 9.3 (3.2)
Anxiety HADS, mean (SD) 6.5 (3.8) 6.9 (3.7) 6.3 (3.9)
Depression HADS, mean (SD) 6.5 (3.8) 6.9 (3.9) 6.1 (3.7)
Marital status
  Married/living together 122/220 (55.5) 55 (61.1) 67/130 (51.5)
  Single/divorced/widowed 98/220 (44.5) 35 (38.9) 63/130 (48.5)
Both parents born in the Netherlands 186/220 (84.5) 74/90 (82.2) 112/130 (86.2)
Rural residential area 99/236 (41.9) 42 (43.8) 57/140 (40.7)
Unemployed/sick 26/220 (11.8) 12/90 (13.3) 14/130 (10.8)
Level of education
  Low 89/220 (40.5) 33/90 (36.7) 56/130 (43.1)
  Average 60/220 (27.3) 22/90 (24.4) 38/130 (29.2)
  High 71/220 (32.3) 35/90 (38.9) 36/130 (27.7)
Current smoker 39/219 (17.8) 16/90 (17.8) 23/129 (17.8)
Alcohol use above norm 63/219 (28.8) 29/90 (32.2) 34/129 (26.4)
Exercise under norm 141/219 (64.4) 56/90 (62.2) 85/129 (65.9)
BMI, mean (SD) 28.9 (6.1) 29.4 (6.8) 28.5 (5.6)
Locus of control, mean (SD) 7.9 (4.2) 8.3 (4.2) 7.6 (4.1)
Social support, mean (SD) 36.3 (9.2) 35.8 (9.0) 36.7 (9.5)
Dysthymia 13/236 (5.5) 6/96 (6.3) 7/140 (5.0)
Onset of depression after age of 55 101/210 (48.1) 38/89 (42.7) 63/121 (52.1)
Numbers are percentages unless stated otherwise.
BMI, body mass index; HADS, Hospital Anxiety and Depression Scale; ICPC, International Classification of Primary Care; PHQ-9, Patient 
Health Questionnaire-9.
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Table 2 Results of the mixed model and GEE long-term effectiveness analyses
Cumulative incidence 
of depression (n/N) % Intervention Care as usual
Corrected analyses* Crude analyses
OR (95% CI) P values OR (95% CI) P values
Baseline 0 0
T6 (5/84) 6.0 (10/125) 8.0 0.82 (0.19 to 3.51) 0.79 0.90 (0.32 to  2.50) 0.84
T12 (9/82) 11.0 (12/118) 10.2 1.44 (0.46 to 4.47) 0.53 1.20 (0.49 to 2.92) 0.70
T24 (13/77) 16.9 (17/105) 16.2 1.23 (0.50 to 3.02) 0.66 1.11 (0.51 to 2.44) 0.79
Overall effect na na 1.37 (0.52 to 3.55) 0.52 1.11 (0.49 to 2.49) 0.80
PHQ mean (SD) Intervention Care as usual
Corrected analyses* Crude analyses
B (95% CI) P values B (95% CI) P values
Baseline 9.53 (3.14) 9.28 (3.23) 
T3 6.68 (4.55) 6.58 (4.21) −0.39 (–1.52 to 0.74) 0.50 −0.03 (–1.17 to 1.11) 0.96
T6 6.10 (4.43) 6.12 (4.41) −0.37 (–1.50 to 0.76) 0.52 −0.17 (–1.30 to 0.95) 0.76
T9 6.28 (4.31) 6.46 (4.51) −0.48 (–1.62 to 0.65) 0.40 −0.40 (–1.53 to 0.73) 0.49
T12 6.60 (5.23) 6.29 (4.46) −0.09 (–1.20 to 1.02) 0.88 −0.03 (–1.13 to 1.07) 0.96
T24 5.81 (4.76) 5.15 (4.33) 0.00 (–1.18 to 1.19) 0.88 0.02 (–1.15 to 1.19) 0.97
Overall effect   na na 0.29 (–1.15 to 0.58) 0.52 −0.13 (–0.99 to 0.73) 0.77
Perceived recovery 
(%) Intervention Care as usual
Corrected analyses* Crude analyses
OR (95% CI) P values OR (95% CI) P values
Baseline na na 
T3 40.3% 49.5% 0.78 (0.42 to 1.45) 0.44 0.64 (0.36 to 1.15) 0.14
T6 48.8% 45.5% 1.46 (0.79 to 2.69) 0.23 1.15 (0.65 to 2.02) 0.64
T9 55.0% 48.7% 1.47 (0.79 to 2.75) 0.22 1.30 (0.74 to 2.30) 0.91
T12 55.6% 58.1% 1.04 (0.56 to 1.92) 0.91 0.91 (0.51 to 1.61) 0.74
T24 68.0% 57.1% 2.38 (1.21 to 4.67) 0.01 2.04 (1.08 to 3.87) 0.03
Overall effect na na 1.32 (0.87 to 2.00) 0.19 1.10 (0.75 to 1.62) 0.61
HADS-A mean (SD) Intervention Care as usual
Corrected analyses* Crude analyses
B (95% CI) P values B (95% CI) P values
Baseline 6.91 (3.74) 6.25 (3.90) 
T3 6.35 (4.04) 6.29 (3.97) −0.27 (−1.13 to 0.60) 0.54 −0.13 (−1.00 to 0.74) 0.76
T6 5.70 (4.10) 6.63 (4.00) −1.04 (–1.91 to −0.18) 0.02 −1.04 (–1.91 to −0.18) 0.02
T9 6.16 (4.24) 6.03 (4.04) −0.49 (–1.35 to 0.38) 0.27 −0.45 (–1.31 to 0.42) 0.31
T12 5.77 (4.69) 5.83 (3.99) −0.50 (–1.37 to 0.38) 0.27 −0.43 (–1.31 to 0.44) 0.33
T24 5.45 (4.46) 5.06 (3.90) −0.59 (–1.50 to 0.31) 0.20 −0.48 (–1.38 to 0.43) 0.30
Overall effect   na na −0.59 (–1.23 to 0.06) 0.08 −0.52 (–1.17 to 0.13) 0.12
HADS-D mean (SD) Intervention Care as usual
Corrected analyses* Crude analyses
B (95% CI) P value B (95% CI) P value
Baseline 6.93 (3.87) 6.11 (3.73) 
T3 6.14 (4.16) 6.21 (3.87) −0.26 (–1.12 to 0.60) 0.55 −0.29 (–1.15 to 0.56) 0.51
T6 5.82 (3.79) 5.75 (4.03) −0.22 (–1.07 to 0.64) 0.62 −0.32 (–1.18 to 0.53) 0.46
T9 6.36 (4.04) 6.07 (4.08) −0.21 (–1.06 to 0.65) 0.63 −0.24 (–1.09 to 0.61) 0.58
T12 6.09 (4.20) 6.11 (4.22) −0.41 (–1.27 to 0.46) 0.36 −0.50 (–1.36 to 0.36) 0.26
T24 5.59 (4.66) 4.92 (3.90) −0.41 (–1.30 to 0.48) 0.37 −0.48 (–1.37 to 0.41) 0.29
Overall effect   na na −0.30 (–0.94 to 0.33) 0.35 −0.37 (–1.00 to 0.26) 0.25
*Corrected for: baseline values of the outcome, age, gender, marital status, employment status, level of education, coexistence of DM2 and 
CHD, alcohol use, number of depressive episodes in history and age of onset of depression. The baseline value of the outcome is not added 
as an extra variable in the corrected analyses of the overall effects since it is already incorporated in the crude overall analyses.
GEE, generalised estimating equations; HADS-A, Hospital Anxiety and Depression Scale-Anxiety; HADS-D, Hospital Anxiety and Depression 
Scale-Depression; na, not applicable; PHQ-9, Patient Health Questionnaire-9.
 o
n
 30 N
ovem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020412 on 28 October 2018. Downloaded from 
7Pols AD, et al. BMJ Open 2018;8:e020412. doi:10.1136/bmjopen-2017-020412
Open access
of (somatic) symptoms of the chronic disease and those 
of depression.53
In a previous publication, we have hypothesised the 
causes for the lack of effect of the Step-Dep intervention 
as compared with care as usual in preventing incident 
MDD at 12 months of follow-up,20 which we assume also 
explain the lack of effect at 24 months of follow-up. In 
summary, a first explanation could be that subthreshold 
depression was potentially overdiagnosed in our popu-
lation, whereas stepped-care may be more effective in 
patients with more severe symptoms.54 Second, fewer 
patients than expected were treated with the more inten-
sive treatment steps. This was partly caused by the fact 
that a considerable proportion of patients did not want 
to start one or more of the treatment steps. This may indi-
cate that our programme did not sufficiently match their 
need for care. Furthermore, this was in part due to the 
low PHQ-9 scores of 6.7 on average at 3 months after base-
line measurements, which made only a relatively small 
proportion of the patients eligible for more intensive 
treatment steps. The drop in PHQ-9 scores between base-
line and 3 months of follow-up in both groups exceeded 
the expectations of spontaneous recovery alone.55 It is 
unlikely that either of the groups received any specific 
treatment during this period. The Step-Dep programme 
entailed an initial period of watchful waiting and Dutch 
primary care clinical guidelines recommend a similar 
waiting period before starting treatment for subthreshold 
depression.56 Additionally, screening for depression 
alone does not change the management of depression in 
primary care.57 We argue that the decrease in depressive 
symptoms may partly be caused by attention, regression to 
the mean or patients' self-insight into their mental symp-
toms and problems. Finally, depressive and anxiety symp-
toms slightly improved over time in both groups, possibly 
indicating that usual care is already of reasonable quality 
and, therefore, the room for improvement for new inter-
ventions over usual care may be limited.
We observed a remarkable drop between baseline and 
3 months in the PHQ-9, but not for the HADS-D. We can 
only speculate about this difference in drop between 
PHQ-9 and HADS-D at 3 months. Currently, we have no 
solid explanation for this difference. There is a possi-
bility of a statistical artefact. The PHQ-9 is made to align 
with Diagnostic and Statistical Manual of Mental Disor-
ders diagnostic symptoms of depression irrespective 
of the comorbid presence of physical conditions, while 
the HADS-D should be robust for physical illnesses and 
perhaps measures a broader construct (for instance, 
‘I can laugh and see the funny side of things’). We do 
think that the different sensitivity of these instruments 
have minimal implications, if at all, for the intervention 
algorithm of the Step care approach. In the Step-Dep 
effectiveness study,20 we used the MINI, the PHQ-9, the 
HADS-D and HADS-A to look at the differences in inci-
dent major depression and depression and anxiety levels, 
respectively. All instruments used are valid and reliable. 
We found no statistically significant differences at any 
time point nor a statistically significant difference in 
the course of incident MDD or depression and anxiety 
symptom levels over time between the groups. In other 
words, the slope of the different outcomes over time was 
virtually the same.
Our multivariable model consisted of 4 predictors of 
MDD incidence. First, baseline depression severity level is 
the most frequently found and often strongest predictor 
of incident depression in other studies in patients with 
DM221 22 25 or CHD.27 30 31 In line with these findings, in 
our model, a clinically relevant baseline difference in 
depressive symptoms of 5 points on the PHQ-9 translated 
to an almost 5 times increased risk of developing a MDD 
during 2 years. This factor was used as a continuous vari-
able in which the severity level predicts the occurrence 
of a depressive episode, which supports the concept of 
a gradual risk of depression. Second, the anxiety level at 
baseline was an important predictor of MDD. Anxiety has 
been frequently appointed as an important risk factor for 
depression in DM221 and CHD populations.29 30 Predic-
tors are not necessarily aetiological factors.58 Nonethe-
less, as anxiety is also known for its high comorbidity 
with depression, the assumption that reducing anxiety 
will have a positive effect on depressive symptoms and 
MDD incidence seems defendable. Third, the risk the 
Table 3 Multivariable prediction model of incident 
depression during 2-year follow-up
Predictor RC OR 95% CI P value
  Female sex – – – 
  Age – – – 
Somatic disorder – – – 
DM2 
CHD 
DM2 and CHD 
History of depression – – – 
Baseline depression 
scores
0.32 
p.p.i.
1.37 1.20 to  1.55 0.00
Baseline anxiety 
scores
0.12 
p.p.i.
1.13 1.02 to 1.25 0.01
Stressful life event in 
past year
0.74 2.10 1.02 to 4.32 0.04
>3 chronic illnesses 0.78 2.19 1.12 to 4.25 0.02
Randomisation 
status I versus C
0.14 1.15 0.58 to 2.29 0.68
An OR >1 reflects a higher probability the outcome 
an incident depression and an OR <1 reflects a lower 
probability compared with the reference category. OR 
estimated after multiple imputation (n=25 data sets) 
with p value of 0.157. Linear predictor corrected 
after bootstrapping=−4.1147 + 0.131*Randomisation 
status+0.7167*>3 chronic illnesses+0.680*stressful life event 
in past year+0.1118*baseline anxiety scores+0.2868*baseline 
depression scores.
CHD, coronary heart disease; DM2, diabetes mellitus type 2; 
p.p.i., per point increase; RC,  regression coefficient. 
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occurrence of stressful life events poses has been demon-
strated before in patients with CHD.27 Although most 
of our knowledge on the role of stressful life events as 
predictors of depression cover a short period of time,59 
more recent research has shown their long-term risk.60 
This would imply that healthcare providers should not 
only be temporarily alert on the negative influence on 
mental health of stressful life events, but should also be 
aware of deferred effects. Fourth, the presence of more 
than 3 chronic diseases was identified as a predictor of 
MDD in our study, in concordance with results in a DM2 
population of Fisher et al.24 Interestingly, the presence 
of either DM2, CHD or both was not a predictor in our 
study, which suggests that these patients are at the same 
risk of incident depression. As all included patients in 
Fisher’s and our study had at least one chronic disease, 
a discrimination between the predictive values of no 
chronic disease versus only one versus multiple chronic 
diseases could not be made. The specific importance of 
an increased number of diseases as opposed to the risk of 
a chronic disease has also been demonstrated previously 
in a primary care population with subthreshold depres-
sion61 and several elderly populations.62 Why the number 
of diseases would matter in itself can perhaps be under-
stood from findings from qualitative interviews. Step-Dep 
patients explained that chronic diseases indirectly lead 
to depression, as they diminish future perspectives and 
cause disability (Pols, submitted), which might be subjec-
tive to a certain ‘threshold’ burden of disease. Finally, 
in contrast to findings in multiple other studies, female 
sex24 26 28 30 and a history of depression25 26 28 did not 
predict incident MDD in our study. These factors were 
also not univariately associated with incident depression 
in our data. A history of depression was self-reported in 
our study. Perhaps patients over-reported this, as it was 
not required that they received treatment for this depres-
sive episode, which might explain the lack of a univariate 
correlation with incident depression.
The model rendered in this study had good discrim-
inative properties with an AUC of 0.80 with the use of 
only 4 predictors that are relatively easily obtained by the 
GP. This makes this prediction model practically viable. It 
could assist as a tool to both improve the (early) recogni-
tion of depression in primary care patients with DM2 and/
or CHD and indicate which patients need further care. 
As chronic care in the Netherlands is being delegated 
more and more to primary care practice nurses, such 
a tool might prove useful in their and the GPs’ regular 
check-ups. In practice, this would not only entail that in 
patients with DM2 and/or CHD, GPs and practice nurses 
standardly inquire about symptoms of depression and 
anxiety during regular checkups, but also that in those 
with multiple chronic diseases next to their DM2 or CHD, 
who suffered a recent stressful life event, the presence and 
course of depressive and anxiety symptoms are assessed 
and monitored over time with, for example, the PHQ-9 
and HADS. Whenever depressive or anxiety symptoms 
are clinically severely elevated or significantly deteriorate 
over time, treatment should be offered according to the 
patients’ need for care. By reducing both depressive and 
anxiety symptoms, perhaps MDD and its negative conse-
quences can be averted.
Future research should focus on the external validation 
to test the generalisability of our results, for example, on 
patients with DM2 and/or CHD without subthreshold 
depression, or outside the Dutch setting. Subsequently, 
studies are required to investigate the influence of 
the prediction model on decision making and patient 
outcomes. Consecutively, future research should evaluate 
whether the suggested enhanced vigilance strategies in 
combination with depression prevention programmes 
that only target those with all 4 indicated predictors 
present and aim to reduce both anxiety and depressive 
symptoms are cost-effective.63
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